Tesamorelin Acetate Patent Expiration
Tesamorelin Acetate is used for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. It was first introduced by Emd Serono Inc
Tesamorelin Acetate Patents
Given below is the list of patents protecting Tesamorelin Acetate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Egrifta | US7316997 | GH secretagogues and uses thereof |
Aug 14, 2023
(Expired) | Emd Serono |
| Egrifta | US8314066 | GH secretagogues and uses thereof |
Aug 14, 2023
(Expired) | Emd Serono |
| Egrifta | US8435945 | GH secretagogues and uses thereof |
Aug 14, 2023
(Expired) | Emd Serono |
| Egrifta | US7144577 | Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy |
Jul 14, 2020
(Expired) | Emd Serono |
| Egrifta | US5861379 | Chimeric fatty body-pro-GRF analogs with increased biological potency |
May 26, 2015
(Expired) | Emd Serono |
| Egrifta | US6020311 | GRF analogs with increased biological potency |
May 26, 2015
(Expired) | Emd Serono |
Tesamorelin Acetate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List